Navigation Links
TAK-390MR Phase 3 data presented at Digestive Disease Week
Date:5/19/2008

SAN DIEGO, Calif. May 18, 2008 TAP Pharmaceutical Products Inc. today reported results from three pivotal Phase 3 studies evaluating investigational new drug TAK-390MR, the first proton pump inhibitor (PPI) with an innovative dual delayed release technology, in healing patients with erosive esophagitis (EE) and in maintenance of healed EE. The data were presented at the Digestive Disease Week (DDW) annual meeting in San Diego.

The innovative dual delayed release technology delivers TAK-390MR in two separate releases, which is a first in the PPI class and makes TAK-390MR a very interesting potential future treatment option, said Dr. David Peura, professor of medicine, University of Virginia Health System, past president of the American Gastroenterological Association.

Data from the two separate EE healing studies demonstrated that patients treated with TAK-390MR 60 mg and 90 mg experienced higher overall healing after eight weeks, versus patients taking lansoprazole 30 mg. In addition, data from a six-month maintenance of healed EE study demonstrated that patients treated with TAK-390MR 30 mg and 60 mg experienced statistically significant overall maintenance and symptom relief over placebo.

Healing of Erosive Esophagitis Studies

TAK-390MR was compared to lansoprazole in two identically designed, double-blind, randomized, controlled trials in patients with confirmed EE. A total of 4,092 patients were enrolled in the two global studies. The primary objective was to evaluate overall healing rates over eight weeks after once-daily administration of TAK-390MR 60 mg or 90 mg or lansoprazole 30 mg. The results for each study were analyzed using life table and crude rate methods.

Results from these trials demonstrated that TAK-390MR 60 mg and 90 mg produced consistently high healing rates for patients with EE. In one study, the life table analysis showed that 93 percent and 95 percent of TAK-390MR patients (60 mg a
'/>"/>

Contact: Kelly Thornicroft
kthronicroft@wcpglobal.com
773-405-4515
WeissComm Partners
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Ovation further advances development pipeline with new phase III epilepsy study
2. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
3. Mannatech Launches Phase One of New Sales and Training Tools
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Manic phase of bipolar disorder benefits from breast cancer medication
6. ARIZONA METH PROJECT Unveils Arizonas Anti-Meth Youth Pledge and Kicks Off Phase Two of Public Awareness Campaign
7. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
8. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R)
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Responding to the call to ... to an increasingly diverse patient population, three leading ... expertise to the publication of a new textbook ... and Cultural Competence in Health Care: A Systems ... a professor in the Management Division at the ...
(Date:7/30/2014)... returning National Guard soldiers were more likely to ... life setbacks, including job loss, legal problems, divorce, ... military families. Results of the study by researchers ... are published online in the American Journal ... a major concern for reservists returning home. Nearly ...
(Date:7/30/2014)... Recently, the Kansas Health Image ... start-up fees for hospitals and clinics who request ... September 30, 2014. , Modern healthcare providers are ... complexity of digital patient information, often referred to ... data silos. , Traditional health IT solutions, including ...
(Date:7/30/2014)... 2014 MyMobileUniversity (MMU) is a global ... an award winning mobile and web based learning company ... 2004. , MyMobileUni.com’s platform makes it a one-stop centre ... has links to the world’s leading Massive Open Online ... experts from all over the world who have content ...
(Date:7/30/2014)... Daily Gossip mentions that the "Panic Away" method developed ... stop anxiety and eliminate all associated symptoms. It has been ... 150,000 people in getting their lives back. , The Panic ... system that will teach sufferers different techniques on how to ... to access, as it is available in a complex guide. ...
Breaking Medicine News(10 mins):Health News:NLN CEO Co-Authors Textbook to Advance Diversity and Cultural Competence Across Health Care Professions 2Health News:NLN CEO Co-Authors Textbook to Advance Diversity and Cultural Competence Across Health Care Professions 3Health News:Vets' alcohol problems linked to stress on the home front 2Health News:Kansas Health Image Exchange Announces Open Enrollment; Virtual CD from Offsite Image Solves Problems with Unreadable Patient Images, Delayed Diagnosis 2Health News:Kansas Health Image Exchange Announces Open Enrollment; Virtual CD from Offsite Image Solves Problems with Unreadable Patient Images, Delayed Diagnosis 3Health News:MyMobileUniversity Inviting Individuals, Who Are Passionate about the Universal Right to Education, to Come on Board as Goodwill Ambassadors 2Health News:MyMobileUniversity Inviting Individuals, Who Are Passionate about the Universal Right to Education, to Come on Board as Goodwill Ambassadors 3Health News:Panic Away Review Reveals How to Stop Anxiety 2
... (OTC,Bulletin Board: SNKTY), a Life Sciences company engaged ... of healthy aging, today announced,that Dr. Neil Sadick ... the American Academy of Dermatology in San Antonio, ... Dr. Sadick, a prominent New York,dermatologist, outlined the ...
... patients receiving aggressive drug therapy to cut blood sugar ... large North American trial designed to aggressively lower the ... heart disease has been halted because of an unexpected ... , Federal health officials announced Wednesday that 257 ...
... Senetek PLC (OTC,Bulletin Board: SNKTY), a Life ... target the science of healthy aging, today announced,the ... ., Mr. Frank Massino, Senetek,s Chairman and ... greater visibility to Senetek at this,significant time in ...
... Introduced during the much anticipated ... America., TORONTO, Feb. 6 /PRNewswire/ - IgeaCare Systems ... introduction of,ConversationPRO(TM) for Microsoft Dynamics CRM 4.0., "Contact ... CRM,screen launch populated with the caller contact information, along ...
... ST. LOUIS, Feb. 6 Cejka Search, ... firm, recently announced that,several of its leaders ... Retention Strategies Audio Conference and the American,College ... Leadership., Audio Conference: Retention Strategies to ...
... CHAPEL HILL, N.C., Feb. 6 From ... improvements, customer feedback has,enhanced services, products and ... recent study by Best Practices, LLC,s Global ... initiatives is key,to better aligning the customer ...
Cached Medicine News:Health News:Dr. Neil Sadick Presents on Pyratine-6(TM) at the Annual Meeting of the American Academy of Dermatology 2Health News:Deaths Halt Part of Large Diabetes Trial 2Health News:Deaths Halt Part of Large Diabetes Trial 3Health News:Deaths Halt Part of Large Diabetes Trial 4Health News:Senetek PLC Announces Launch of New Website 2Health News:Microsoft Dynamics CRM 4.0 Users now can include Telephony and Call Recording features by adding ConversationPRO(TM) from VoiceGate, a Division of IgeaCare Systems Inc. 2Health News:Microsoft Dynamics CRM 4.0 Users now can include Telephony and Call Recording features by adding ConversationPRO(TM) from VoiceGate, a Division of IgeaCare Systems Inc. 3Health News:Cejka Search Experts Present Latest Developments in Physician Retention and CEO Leadership Skills 2Health News:Customer Experience Conference, Feb. 25-27: Sharing New Insights on Winning Customer Loyalty 2
(Date:7/30/2014)... YORK , July 30, 2014 ACCESS ... for oncology supportive care, announced that its novel product ... in an article on OncLive.com titled, "Study Finds Mouth ... Cancers."  Dr. Steve Sonis , a leading expert ... seen in the oncology community for evidence-based strategies for ...
(Date:7/30/2014)... 2014  Hospira, Inc. (NYSE: HSP ... and infusion technologies, today reported results for the ... for the quarter were $1.1 billion and adjusted* ... exclude specified items as described later in this ... U.S. Generally Accepted Accounting Principles (GAAP) basis, second-quarter ...
(Date:7/30/2014)... July 30, 2014   Epic Sciences, Inc. ... designs and develops novel diagnostics to personalize and ... today the completion of a $30 million Series ... investors RusnanoMedInvest (RMI) and Arcus Ventures, existing investors ... Investments, as well as undisclosed individual investors. With ...
Breaking Medicine Technology:Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25Hospira Reports Second-Quarter 2014 Results 26Hospira Reports Second-Quarter 2014 Results 27Hospira Reports Second-Quarter 2014 Results 28Hospira Reports Second-Quarter 2014 Results 29Hospira Reports Second-Quarter 2014 Results 30Hospira Reports Second-Quarter 2014 Results 31Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 2Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 3
For the quantitative in vitro determination of Uric Acid in serum, plasma and urine...
The BUN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of urea nitrogen in serum, plasma and urine....
For the quantitative in vitro determination of K-glutamyl transferase (K-GT) in serum or plasma....
The CK method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase activity in serum and plasma...
Medicine Products: